Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 1.00 |
| ▸ | PTPRC | P08575 | 8/20 | 1.00 |
| ▸ | PTPRF | P10586 | 2/20 | 1.00 |
| ▸ | CDC25B | P30305 | 2/20 | 1.00 |
| ▸ | BACE1 | P56817 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808966 | 1.00 | PTPN1 (1.00) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| Dimethylamine SCHEMBL7487471 | 0.92 | PTPN1 (0.85) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL30433091 | 0.86 | PTPN1 (0.76) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL5139479 | 0.86 | PTPN1 (0.76) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| Diethylamine SCHEMBL7475236 | 0.86 | PTPN1 (0.74) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL8600693 | 0.86 | PTPN1 (0.75) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL6236908 | 0.86 | PTPRC (1.00) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL29673492 | 0.83 | BACE1 (1.00) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL5485068 | 0.83 | BACE1 (1.00) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL7487467 | 0.80 | PTPN1 (0.67) | PTPN1PTPRCPTPRFCDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805398-A | Preparation method of ecteinascidin compound | 江苏恒瑞医药股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114805398-A | Preparation method of ecteinascidin compound | 江苏恒瑞医药股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20190022084-A1 | PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-01-24 | — | — | US | disclosed |
| EP-2502623-B1 | Promoting Axon Regeneration in the Adult CNS through Control of Protein Translation | CHILDRENS MEDICAL CENTER (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20140213609-A1 | PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213609-A1 | PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-07-31 | — | — | US | disclosed |
| US-8728756-B2 | Promoting axon regeneration in the adult CNS through control of protein translation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-8728756-B2 | Promoting axon regeneration in the adult CNS through control of protein translation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130123228-A1 | PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123228-A1 | PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
| US-20090305333-A1 | Promoting Axon Regeneration in the Adult CNS through Control of Protein Translation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-10 | — | — | US | disclosed |
| US-20090305333-A1 | Promoting Axon Regeneration in the Adult CNS through Control of Protein Translation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-10 | — | — | US | disclosed |
| WO-2009149435-A2 | PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20070203098-A1 | Pten Inhibitors | SEMAFORE PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203098-A1 | Pten Inhibitors | SEMAFORE PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-6939896-B2 | Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| EP-1259231-B1 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| US-20030119897-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1259231-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001045681-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123228-A1 | PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | GAP43, BDNF, DCX | PTPN1 4105/4885PTPRC 1471/4885PTPRF 1572/4885 |
| US-20190022084-A1 | PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | GAP43, BDNF, PMP22 | PTPN1 1080/4885PTPRC 144/4885PTPRF 95/4885 |
| US-20030119897-A1 | Cd45 inhibitors | PTPRC, CD2, HLA-C | PTPN1 18/4885PTPRC 1/4885PTPRF 27/4885 |
| US-20070203098-A1 | Pten Inhibitors | PTEN, MTMR1, PTPRJ | PTPN1 64/4885PTPRC 12/4885PTPRF 17/4885 |
| US-20140213609-A1 | PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION | GAP43, DCX, BDNF | PTPN1 3922/4885PTPRC 1242/4885PTPRF 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.